Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.
IPO Year:
Exchange: NASDAQ
Website: lexariabioscience.com
3 - Lexaria Bioscience Corp. (0001348362) (Issuer)
4 - Lexaria Bioscience Corp. (0001348362) (Issuer)
4 - Lexaria Bioscience Corp. (0001348362) (Issuer)
4 - Lexaria Bioscience Corp. (0001348362) (Issuer)
4 - Lexaria Bioscience Corp. (0001348362) (Issuer)
4 - Lexaria Bioscience Corp. (0001348362) (Issuer)
4 - Lexaria Bioscience Corp. (0001348362) (Issuer)
4 - Lexaria Bioscience Corp. (0001348362) (Issuer)
4 - Lexaria Bioscience Corp. (0001348362) (Issuer)
4 - Lexaria Bioscience Corp. (0001348362) (Issuer)
8-K - Lexaria Bioscience Corp. (0001348362) (Filer)
8-K - Lexaria Bioscience Corp. (0001348362) (Filer)
424B5 - Lexaria Bioscience Corp. (0001348362) (Filer)
8-K - Lexaria Bioscience Corp. (0001348362) (Filer)
10-Q - Lexaria Bioscience Corp. (0001348362) (Filer)
EFFECT - Lexaria Bioscience Corp. (0001348362) (Filer)
424B3 - Lexaria Bioscience Corp. (0001348362) (Filer)
S-1 - Lexaria Bioscience Corp. (0001348362) (Filer)
D - Lexaria Bioscience Corp. (0001348362) (Filer)
8-K - Lexaria Bioscience Corp. (0001348362) (Filer)
KELOWNA, BC / ACCESSWIRE / March 14, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of Nelson Cabatuan, CPA, as Chief Financial Officer (CFO) effective immediately. As a member of the executive leadership team, Mr. Cabatuan will lead the Company's financial operations."Nelson's deep financial leadership experience will be instrumental to the execution of Lexaria's long-term growth strategy as we continue to maximize the potential use of our DehydraTECH platform for GLP-1 and other therapeutic applications with high unmet medical needs," said Chris Bunka, Chief Executive Officer
KELOWNA, BC / ACCESSWIRE / April 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the appointment of a new Chief Financial Officer and the issuance of share purchase warrants to third party consultants.Lexaria is pleased to announce that effective April 15, 2021, Gregory Downey will be assuming the role of Chief Financial Officer of the Company. During the past two years, Mr. Downey has been engaged by the Company as its Controller and has intimate knowledge regarding the Company's business and finances. Mr. Downey brings a wealth of experience to Lexaria, having served as the Chief
SC 13D/A - Lexaria Bioscience Corp. (0001348362) (Subject)
SC 13D/A - Lexaria Bioscience Corp. (0001348362) (Subject)
SC 13D/A - Lexaria Bioscience Corp. (0001348362) (Subject)
SC 13G/A - Lexaria Bioscience Corp. (0001348362) (Subject)
SC 13D - Lexaria Bioscience Corp. (0001348362) (Subject)
SC 13G/A - Lexaria Bioscience Corp. (0001348362) (Subject)
4 - Lexaria Bioscience Corp. (0001348362) (Issuer)
KELOWNA, BC / ACCESSWIRE / September 5, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this letter from outgoing Chief Executive Officer ("CEO") Chris Bunka as a strategic update to all stakeholders.CEO LETTER TO STAKEHOLDERSIt is with mixed emotions and a heavy heart that I write my final strategic letter to my Lexaria family. Lexaria has been "home" for 16 years, and, similar to raising a family, there have been difficult times that test your resolve, and many other times of incredible joy and pride.Many people will focus on the "why". There is just one, fairly simple reason: Lexa
KELOWNA, BC / ACCESSWIRE / September 3, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has entered into a Material Transfer Agreement with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECHTM technology in a pre-clinical setting.Under the terms of the agreement, Lexaria is responsible for formulation and supply of certain DehydraTECH compositions. The pharmacokinetics of DehydraTECH compositions will be evaluated in animal studies. Lexaria has awarded to PharmaCO a temporary exclusive license option limited to specific DehydraTECH concepts and formulations under exa
Absorption improvements appear to continue with DehydraTECH-processed Rybelsus® vs. Rybelsus® tablets even under "fed" conditionsDehydraTECH-treated Rybelsus® does absorb through a mouth-melt product format KELOWNA, BC / ACCESSWIRE / August 29, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that tolerability and additional pharmacokinetic ("PK") results from human pilot study #2, GLP-1-H24-2, (the "Study") have been received. Lexaria's DehydraTECH-processed Rybelsus® capsules demonstrated superior tolerability in delivering the GLP-1 drug semaglutide versus commercially available Rybelsus®.We w
Trend toward higher overall absorption under fed conditions evidenced with DehydraTECH®-processed Rybelsus® KELOWNA, BC / ACCESSWIRE / August 27, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that the first results from human pilot study #2, GLP-1-H24-2 (the "Study"), have been received. Lexaria's DehydraTECH®-processed Rybelsus® evidenced a trend toward higher overall absorption compared to Rybelsus® that was not processed with DehydraTECH.Since Lexaria has already demonstrated superior pharmacokinetic performance of its DehydraTECH-processed Rybelsus® under the recommended dosing conditions
DehydraTECH-liraglutide is outperforming DehydraTECH-semaglutideSelect DehydraTECH-CBD formulations appear to continue to outperform DehydraTECH-semaglutide KELOWNA, BC / ACCESSWIRE / August 22, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received and can now report on 8-week body weight results from ongoing animal study WEIGHT-A24-1 (the "Study").This Study is the only study carried out anywhere in the world today, to evaluate the relative performance of liraglutide processed with DehydraTECH. In humans, semaglutide has been shown in other studies to be more than twice as effect
Monomeric form of GLP-1 drug preserved by DehydraTECH KELOWNA, BC / ACCESSWIRE / August 19, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces positive findings from its applied research program together with the National Research Council of Canada ("NRC") that evaluated important mode of action facets of DehydraTECH processed with the glucagon-peptide 1 ("GLP-1") drug, semaglutide.This highly technical work program examined the molecular properties of DehydraTECH-processed pure semaglutide in comparison to the commercially available semaglutide formulation Rybelsus® using simulated gastric fluid a
DehydraTECH appears to work with a second GLP-1 drug - liraglutideDehydraTECH appears to be working with semaglutide both with and without SNAC technologyDehydraTECH-CBD is showing strong apparent performance relative to GLP-1Dosing in the final four study arms has now begun KELOWNA, BC / ACCESSWIRE / July 17, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW))) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that interim results from the first four weeks of dosing in its ongoing diabetes animal study WEIGHT-A24-1 (the "Study") have been received and have already produced several noteworthy findings.Unlimited food and water has been provided to the ani
Strategic growth plan execution underway. KELOWNA, BC / ACCESSWIRE / July 16, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces plans for strategic growth."Lexaria has certain initiatives underway that are increasing confidence in our medium-term and longer-term strategies," said Chris Bunka, Chief Executive Officer of Lexaria Bioscience Corp. "As a result of the success we are experiencing and the continued success we are anticipating, we will be implementing a number of strategic steps in the weeks and months to come."Lexaria will be expanding its management team this summer as it prepares for t
All three dosing arms have been completed. KELOWNA, BC / ACCESSWIRE / July 9, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW))) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that human pilot study #2, GLP-1-H24-2, (the "Study") has now completed all dosing.The Study is a three-arm, crossover investigation comparing three 7 mg semaglutide dose formulations:a positive control Rybelsus® swallowed tablet;DehydraTECH-semaglutide swallowed capsules; andfor the first time ever, an in-mouth dissolvable DehydraTECH-semaglutide oral tablet.The final DehydraTECH Study arm used a Rybelsus® composition processed with DehydraTECH that is compliant with the U.S.
Lexaria currently holding 46 granted patents worldwide KELOWNA, BC / ACCESSWIRE / July 8, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces three new patent awards.In the European Union, the Company has received a new granted patent in Lexaria's patent family #6: Transdermal and/or Dermal Delivery of Lipophilic Active Agents. This is the Company's second granted patent in this patent family with an earlier patent granted in Canada. This patent will expire in 2039, if not extended and was validated in the following countries: Austria, Czech Republic, France, UK, Germany, Italy, Poland, Spain, Swede
HC Wainwright & Co. analyst Yi Chen reiterates Lexaria Bioscience (NASDAQ:LEXX) with a Buy and maintains $10 price target.
- Reuters
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces plans for strategic growth."Lexaria has certain initiatives underway that are increasing confidence in our medium-term and longer-term strategies," said Chris Bunka, Chief Executive Officer of Lexaria Bioscience Corp. "As a result of the success we are experiencing and the continued success we are anticipating, we will be implementing a number of strategic steps in the weeks and months to come."Lexaria will be expanding its management team this summer as it prepares for the greater workload of multiple projects and initiatives. The first step is appointin
Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.10) by 30 percent. This is a 64.86 percent increase over losses of $(0.37) per share from the same period last year. The company reported quarterly sales of $84.00 thousand which missed the analyst consensus estimate of $150.00 thousand by 44.00 percent. This is a 8.10 percent increase over sales of $77.71 thousand the same period last year.
HC Wainwright & Co. analyst Yi Chen initiates coverage on Lexaria Bioscience (NASDAQ:LEXX) with a Buy rating and announces Price Target of $10.
Lexaria currently holding 46 granted patents worldwideKELOWNA, BC / ACCESSWIRE / July 8, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces three new patent awards.In the European Union, the Company has received a new granted patent in Lexaria's patent family #6: Transdermal and/or Dermal Delivery of Lipophilic Active Agents. This is the Company's second granted patent in this patent family with an earlier patent granted in Canada. This patent will expire in 2039, if not extended and was validated in the following countries: Austria, Czech Republic, France, UK, Germany, Italy, Poland, Spain, Sweden
Shares of Healthequity Inc (NASDAQ:HQY) rose sharply in today's pre-market trading as the company reported better-than-expected first-quarter financial results. The company reported quarterly earnings of 80 cents per share which beat the analyst consensus estimate of 66 cents, according to data from Benzinga Pro. HealthEquity issued strong FY25 earnings guidance and also issued FY25 revenue guidance with its midpoint above expectations. Healthequity shares jumped 5.9% to $85.98 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers MicroAlgo Inc (NASDAQ:MLGO) rose 209.5% to $4.83 in today's pre-market trading. WiMi Hologram Cloud a
Gainers Cue Health (NASDAQ:HLTH) shares rose 70.1% to $0.09 during Thursday's regular session. The market value of their outstanding shares is at $14.8 million. OneMedNet (NASDAQ:ONMD) shares increased by 29.23% to $2.52. The company's market cap stands at $60.1 million. iSpecimen (NASDAQ:ISPC) shares moved upwards by 22.87% to $0.39. The company's market cap stands at $3.8 million. Xeris Biopharma Holdings (NASDAQ:XERS) shares increased by 18.13% to $2.28. The market value of their outstanding shares is at $338.0 million. Kintara Therapeutics (NASDAQ:KTRA) stock rose 18.01% to $0.32. The market value of their outstanding shares is at $17.7 million. Lexaria Bioscience (NASDAQ:LEXX) sha